Mainz Biomed B.V.
MYNZ
$0.00
Change (1 day)
$1.79
Year High
$0.19
Year Low
Categories
Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics in human genetics. It offers ColoAlert, a colorectal cancer screening test; PancAlert, a product candidate for a pancreatic cancer screening test; GenoStrip to detect pathogens in environments on a molecular genetic basis; and research-use-only and IVD tests. The company was founded in 2008 and is based in Mainz, Germany.
Mainz Biomed B.V. (MYNZ) - Company Outlook
Company Outlook
| Year | Receivables | Debt | Liabilities | Assets | Current Assets |
|---|---|---|---|---|---|
| 2023 | 354.51 K | 349.86 K | 12.16 M | 15.41 M | 8.98 M |
| 2022 | 259.14 K | -13,913,518 | 6.14 M | 20.24 M | 18.38 M |
| 2021 | 17.76 K | -6,151,148 | 3.68 M | 10.04 M | 9.61 M |
| 2020 | 44.24 K | 2.86 M | 3.41 M | 673.27 K | 186.4 K |
| 2019 | 40.8 K | 2.21 M | 2.67 M | 715.96 K | 260.01 K |